No Data
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $18
Express News | Replimune Group Inc : BMO Raises Target Price to $18 From $14
Replimune Seeks FDA Approval For RP1 In Advanced Melanoma Under Accelerated Approval Pathway
Replimune Shares Top 52-Week High After Submitting Application for Melanoma Treatment
Replimune Group Shares Are Trading Higher After the Company Announced It Received Breakthrough Therapy Designation Status for RP1 and Will Submit an RP1 Biologics License Application to the FDA Under an Accelerated Approval Pathway.
Express News | Replimune Receives Breakthrough Therapy Designation for Rp1 and Submits Rp1 Biologics License Application to the FDA Under the Accelerated Approval Pathway
No Data
No Data
